Cargando…
Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071094/ https://www.ncbi.nlm.nih.gov/pubmed/34788812 http://dx.doi.org/10.1093/ibd/izab270 |
| _version_ | 1784700776014151680 |
|---|---|
| author | Hanzel, Jurij Dreesen, Erwin Vermeire, Séverine Löwenberg, Mark Hoentjen, Frank Bossuyt, Peter Clasquin, Esmé Baert, Filip J D’Haens, Geert R Mathôt, Ron |
| author_facet | Hanzel, Jurij Dreesen, Erwin Vermeire, Séverine Löwenberg, Mark Hoentjen, Frank Bossuyt, Peter Clasquin, Esmé Baert, Filip J D’Haens, Geert R Mathôt, Ron |
| author_sort | Hanzel, Jurij |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9071094 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Oxford University Press |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90710942022-05-06 Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study Hanzel, Jurij Dreesen, Erwin Vermeire, Séverine Löwenberg, Mark Hoentjen, Frank Bossuyt, Peter Clasquin, Esmé Baert, Filip J D’Haens, Geert R Mathôt, Ron Inflamm Bowel Dis Corrigenda Oxford University Press 2021-11-12 /pmc/articles/PMC9071094/ /pubmed/34788812 http://dx.doi.org/10.1093/ibd/izab270 Text en © 2021 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
| spellingShingle | Corrigenda Hanzel, Jurij Dreesen, Erwin Vermeire, Séverine Löwenberg, Mark Hoentjen, Frank Bossuyt, Peter Clasquin, Esmé Baert, Filip J D’Haens, Geert R Mathôt, Ron Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study |
| title | Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study |
| title_full | Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study |
| title_fullStr | Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study |
| title_full_unstemmed | Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study |
| title_short | Corrigendum to: Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients with Crohn Disease: Posthoc Analysis of the LOVE-CD Study |
| title_sort | corrigendum to: pharmacokinetic-pharmacodynamic model of vedolizumab for targeting endoscopic remission in patients with crohn disease: posthoc analysis of the love-cd study |
| topic | Corrigenda |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9071094/ https://www.ncbi.nlm.nih.gov/pubmed/34788812 http://dx.doi.org/10.1093/ibd/izab270 |
| work_keys_str_mv | AT hanzeljurij corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT dreesenerwin corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT vermeireseverine corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT lowenbergmark corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT hoentjenfrank corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT bossuytpeter corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT clasquinesme corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT baertfilipj corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT dhaensgeertr corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy AT mathotron corrigendumtopharmacokineticpharmacodynamicmodelofvedolizumabfortargetingendoscopicremissioninpatientswithcrohndiseaseposthocanalysisofthelovecdstudy |